162 related articles for article (PubMed ID: 7498292)
1. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors.
Chow L; De Gasparo M; Levens N
Eur J Pharmacol; 1995 Aug; 282(1-3):77-86. PubMed ID: 7498292
[TBL] [Abstract][Full Text] [Related]
2. Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance.
Chow L; De Gasparo M; Levens N
Eur J Pharmacol; 1997 Jan; 319(1):77-83. PubMed ID: 9030901
[TBL] [Abstract][Full Text] [Related]
3. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats.
Webb RL; Navarrete AE; Davis S; de Gasparo M
J Hypertens; 1998 Jun; 16(6):843-52. PubMed ID: 9663925
[TBL] [Abstract][Full Text] [Related]
5. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Ke YS; Cao H; Yang T
Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
[TBL] [Abstract][Full Text] [Related]
7. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits.
Li J; Hirose N; Kawamura M; Arai Y
Atherosclerosis; 1999 Apr; 143(2):315-26. PubMed ID: 10217360
[TBL] [Abstract][Full Text] [Related]
8. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats.
Scheidegger KJ; Wood JM; van Essen H; Struijker-Boudier HA
J Pharmacol Exp Ther; 1996 Sep; 278(3):1276-81. PubMed ID: 8819512
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
[TBL] [Abstract][Full Text] [Related]
11. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Lassila M; Finckenberg P; Pere AK; Krogerus L; Ahonen J; Vapaatalo H; Nurminen ML
Br J Pharmacol; 2000 Jul; 130(6):1339-47. PubMed ID: 10903974
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
Yagi S; Morita T; Katayama S
Hypertens Res; 2004 Feb; 27(2):129-35. PubMed ID: 15005276
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
[TBL] [Abstract][Full Text] [Related]
14. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.
Higashiura K; Ura N; Takada T; Li Y; Torii T; Togashi N; Takada M; Takizawa H; Shimamoto K
Am J Hypertens; 2000 Mar; 13(3):290-7. PubMed ID: 10777034
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
[TBL] [Abstract][Full Text] [Related]
18. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
19. Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR).
Webb RL; Navarrete AE; Davis S
Am J Hypertens; 1998 Jan; 11(1 Pt 1):59-65. PubMed ID: 9504451
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Krombach RS; Clair MJ; Hendrick JW; Houck WV; Zellner JL; Kribbs SB; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
Cardiovasc Res; 1998 Jun; 38(3):631-45. PubMed ID: 9747431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
